GENZYME THERAPEUTICS LIMITED
Get an alert when GENZYME THERAPEUTICS LIMITED files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Next accounts due
2026-09-30 (in 4mo)
Last filed for 2024-12-31
Confirmation statement due
2027-01-14 (in 8mo)
Last made up 2025-12-31
Watchouts
Cash
—
Latest balance sheet
Net assets
£47M
0% vs 2023
Employees
—
Average over period
Profit before tax
£0
Period ending 2024-12-31
Watchouts
Facts from the Companies House register and the latest accounts — not a rating
-
Material uncertainty over going concern
As the company is no longer trading and the Directors intend to liquidate the company following the settlement of remaining net assets at a future date yet to be determined, they have prepared the financial statements on a basis other than going concern.
Name history
Renamed 1 time since incorporation
- GENZYME THERAPEUTICS LIMITED 2001-12-21 → present
- TAYVIN 248 LIMITED 2001-11-05 → 2001-12-21
Net assets
2-year trend · vs Industrials median
Accounts
2-year trend · latest reflected 2024-12-31
| Metric | Trend | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Turnover | £0 | £0 | |
| Operating profit | £0 | £0 | |
| Profit before tax | £0 | £0 | |
| Net profit | £0 | £0 | |
| Cash | — | — | |
| Total assets less current liabilities | £47,039,000 | £47,039,000 | |
| Net assets | £47,039,000 | £47,039,000 | |
| Equity | £47,039,000 | £47,039,000 | |
| Average employees | — | — | |
| Wages | — | — |
Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Return on capital employed | 0.0% | 0.0% | |
| Current ratio | 14.11x | 14.11x |
Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.
Audit & accounting basis
- Accounting basis
- FRS 101
- Reporting scope
- Standalone (parent only)
- Auditor
- Forvis Mazars LLP
- Audit opinion
- Unqualified (clean)
- Going concern
- Material uncertainty disclosed
“As the company is no longer trading and the Directors intend to liquidate the company following the settlement of remaining net assets at a future date yet to be determined, they have prepared the financial statements on a basis other than going concern.”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
2 active · 30 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| MOHAMED, Walaa Mostafa Abbas Awad | Director | 2026-02-01 | Oct 1977 | Egyptian |
| MOUSSA, Ahmed Mohamed Moustafa | Director | 2026-02-01 | Aug 1984 | Egyptian |
Show 30 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| BECKER, Marc | Secretary | 2006-05-26 | 2008-07-02 |
| DENNIS, Jonathan Charles | Secretary | 2008-07-02 | 2009-02-23 |
| DROHAN, Paul Victor | Secretary | 2005-11-04 | 2006-05-26 |
| FRANKLIN, Andrew Timothy | Secretary | 2011-06-01 | 2012-12-31 |
| FRENCH, David Allen | Secretary | 2009-02-23 | 2009-10-23 |
| HARROW, Terence Alfred, Dr | Secretary | 2003-11-04 | 2005-11-04 |
| KEANE, Antoinette | Secretary | 2013-01-24 | 2016-09-07 |
| SHORT, John Richard | Secretary | 2001-11-05 | 2003-11-04 |
| SMITH, Suzanne Elaine | Secretary | 2009-10-23 | 2011-04-30 |
| BAIRD, Jessamy Rachel | Director | 2022-10-01 | 2024-03-01 |
| COUSINS, Simon John, Dr | Director | 2003-11-04 | 2005-11-04 |
| DENNIS, Jonathan Charles | Director | 2008-07-02 | 2009-02-23 |
| DROHAN, Paul Victor | Director | 2005-11-04 | 2012-10-31 |
| DUHALDE, Francois-Xavier | Director | 2016-04-01 | 2021-03-31 |
| FARMER, Nicole Suzanne | Director | 2020-05-16 | 2022-10-01 |
| FRANKLIN, Andrew Timothy | Director | 2010-08-10 | 2012-12-31 |
| FULLER, David, Dr | Director | 2006-02-24 | 2007-09-04 |
| GOLDER, Quentin Robert | Director | 2001-11-05 | 2003-11-04 |
| HARRIS, Peter Anthony, Dr | Director | 2009-02-23 | 2012-06-30 |
| INCERTI, Carlo, Dr | Director | 2006-02-24 | 2011-09-15 |
| JOHNSON, Malcolm David | Director | 2003-11-04 | 2006-05-26 |
| KHAN, Usman | Director | 2021-03-31 | 2026-02-01 |
| KUIPER, Peter Sjoerd | Director | 2016-01-28 | 2020-05-16 |
| LENS, Willem Rutger | Director | 2006-02-24 | 2011-12-11 |
| MARTIN, Brendan James | Director | 2009-10-26 | 2016-01-28 |
| PROSSER, Andrew Michael James | Director | 2013-12-16 | 2016-04-01 |
| SHORT, John Richard | Director | 2001-11-05 | 2003-11-04 |
| SMITH, Alan, Dr | Director | 2006-02-24 | 2011-09-14 |
| UBHI, Rippondeep | Director | 2024-03-01 | 2026-02-01 |
| WYZGA, Michael | Director | 2006-02-24 | 2011-06-30 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Aventis Pharma Limited | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2019-04-30 | Active |
| Sanofi-Aventis Uk Holdings Limited | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2016-04-06 | Ceased 2019-04-30 |
Filing timeline
Last 20 of 133 total filings
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2026-02-05 | AP01 | officers | Appoint person director company with name date | |
| 2026-02-05 | TM01 | officers | Termination director company with name termination date | |
| 2026-02-05 | TM01 | officers | Termination director company with name termination date | |
| 2026-02-05 | AP01 | officers | Appoint person director company with name date | |
| 2026-01-05 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2025-12-12 | AA | accounts | Accounts with accounts type full | |
| 2025-05-27 | RP04AP01 | officers | Second filing of director appointment with name | |
| 2025-05-19 | CH01 | officers | Change person director company with change date | |
| 2025-02-09 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2024-07-06 | AA | accounts | Accounts with accounts type full | |
| 2024-03-03 | AP01 | officers | Appoint person director company with name date | |
| 2024-03-01 | TM01 | officers | Termination director company with name termination date | |
| 2024-02-02 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2023-07-18 | AA | accounts | Accounts with accounts type full | |
| 2023-01-06 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2022-10-14 | AP01 | officers | Appoint person director company with name date | |
| 2022-10-14 | TM01 | officers | Termination director company with name termination date | |
| 2022-07-15 | AA | accounts | Accounts with accounts type full | |
| 2022-02-07 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2021-07-28 | AA | accounts | Accounts with accounts type full |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 8
- Capital events
- 0
- Officers appointed
- 2
- Officers resigned
- 2
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.
Year-on-year
FY2023 → FY2024 · period ending 2024-12-31 vs 2023-12-31
-
Turnover
—
Not reported
-
Cash
—
Not reported
-
Net assets
0%
£47,039,000 £47,039,000
-
Employees
—
Not reported
Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers